Ceftaroline: A novel cephalosporin with activity against methicillin-resistant staphylococcus aureus

Clinical Infectious Diseases

Volumn 52, Issue 9, 2011, Pages 1156-1163

  Saravolatz, Louis D ^a   Stein, Gary E ^a   Johnson, Leonard B ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTAROLINE FOSAMIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; ERYTHROMYCIN; LINEZOLID; PENICILLIN BINDING PROTEIN; VANCOMYCIN;

ACINETOBACTER; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTEREMIA; BACTERIAL SKIN DISEASE; CARDIOTOXICITY; CITROBACTER FREUNDII; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; COOMBS TEST; DIARRHEA; DRUG APPROVAL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GRAM POSITIVE BACTERIUM; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; KLEBSIELLA PNEUMONIAE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIDRUG RESISTANCE; NAUSEA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEUS MIRABILIS; PROVIDENCIA; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SERRATIA MARCESCENS; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION;

ADULT; ANIMALS; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS AS TOPIC; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMONIA, BACTERIAL; RABBITS; STAPHYLOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 79953848771     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir147     Document Type: Article

References (28)

1. Marshall WF, Balir JE. The cephalosporins. Mayo Clin Proc 1999; 74:187-95. (Pubitemid 29085217)
2. Pakyz AL, MacDougall C, Oinenen M, Polk RE. Trends in antibacterial use in US academic health centers. Arch Intern Med 2008; 168:2254-60.
3. Brown SD, Traczewski MM. In vitro antimicrobial activity of a new cephalosporin, ceftaroline, and determination of quality control ranges for MIC testing. Antimicrob Agents Chemother 2009; 53:1271-4.
4. Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono type prodrug of antimRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11:2427-37. (Pubitemid 36539379)
5. Kosowski-Shick K, McGhee P, Appelbaum P. Affinity of ceftraoline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Strepotococcus pneumoniae. Antimicrob Agents Chemother 2010; 54:1670-7.
6. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore D. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60:300-11. (Pubitemid 47243878)
7. Ge Y, Biek D, Talbot G. S. In vitro profiling of Ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 2008; 52:3398-407.
8. Saravolatz L, Pawlak J, Johnson L. In vitro acitivity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant and daptomycin-nonsusceptilbe Staphylococcus aureus isolates. Antimicrob Agents Chemother 2010; 54:3027-30.
9. McGee L, Biek D, Ge Y, et al. In vitro evaluation of antimicrobial activity of ceftaroline against cephalosporin- resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2009; 53:552-6.
10. Fenoil A, Aguilar L, Robiedo O, et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 2008; 52:4209-10.
11. Citron D, Tyrrell K, Merriam C, Goldstein E. In vitro activity cef-taroline against 623 diverse strains of anaerobic bacteria. Antimicrob Agents Chemother 2010; 54:1627-32.
12. Vidaillac C, Leonard S, Sadr H, Jones R, Rybak M. In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53:2360-6.
13. Riccobene T, Fang E, Thye DA. A single-and multiple-dose study to determine the safety, tolerability, and pharmacokinetics (PK) of cef-taroline (CPT) administered by intramuscular (IM) injection to healthy subjects [Abstract 1888]. Program and abstracts of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy-46th Annual Meeting of the Infectious Diseases Society of America. Washington, DC: American Society of Microbiology, 2008.
14. Ge JY, Hubbel A. In vitro evaluation of plasma protein binding and metabolic stability of ceftaroline (PPI-0903M) [Abstract 1935]. In: Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, 2006.
15. Riccobene T, Jakate A, Rank D, Thye DA. An open-label pharmaco-kinetic, safety and tolerability study of single-dose intravenous ceftaroline in subjects with end-stage renal disease on intermittent haemodialysis. In: Program and abstracts of the European Congress of Clinical Microbiology and Infectious Diseases. Helsinki, Finland, 2009.
16. Turnidge JD. The pharmacodynamics of b-Lactams. Clin Infect Dis 1998; 27:10-22.
17. Andes D, Craig WA. Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), activity against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target. Antimicrob Agents Chemother 2006; 50:1376-83.
18. Vidaillac C, Leonard SN, Rybak MJ. In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus and heterogeneous vancomycin-intermediate S. aureus in a hollow fiber model. Antimicrob Agents Chemother 2009; 53:4712-7.
19. Jacqueline C, Caillon J, LeMabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother 2007; 51:3397-400. (Pubitemid 350067563)
20. Jacqueline C, Caillon J, LeMabecque V, et al. In vivo activity of a novel antimethicillin-resistant Staphylococcus aureus, cephalosporin, ceftaro-line, against vancomycin-susceptible and -resistant Enterococcus faecalis strains in a rabbit endocarditis model: a comparative study with linezolid and vancomycin. Antimicrob Agents Chemother 2009; 53:5300-2.
21. Jacqueline C, Caillon J, Batard E, et al. Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalo-sporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model. J Antimicrob Chemother 2010; 65:2264-5.
22. Jacqueline C, Arnador G, Caillon J, et al. Efficacy of the new cepha-losporin ceftaroline in the treatment of experimental methicillin-re- sistant Staphylococcus aureus acute osteomyelitis. J Antimicrob Chemother 2010; 65:1749-52.
23. Cottanoud P, Acosta F, Biek D, Cottagnoud M Leib S. Ceftaroline fosamil against penicillin-sensitive and penicillin-resistant Streptococcus pneumoniae in an experimental meningitis model [abstract B702]. In: Program and abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, 2010.
24. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 2007; 51:3612-16. (Pubitemid 47519351)
25. Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3 multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis 2010; 51:641-50.
26. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, double-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51: 1395-405.
27. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med, 1997; 336, 243-50. (Pubitemid 27044625)
28. Ge JY, Liao S, Thye DA, Talbot GH. Ceftaroline (CPT) dose adjustment recommendations for subjects with mild or moderate renal impairment (RI) [Abstract 35]. In: Program and abstracts of the 47th interscience conference on antimicrobial agents and chemotherapy. Chicago, IL, 2007.